D010051DisordersC04.588.322.455C13.351.500.056.630.705C13.351.937.418.685C19.344.410C19.391.630.70543870.915408Ovarian NeoplasmsFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonCancer BiologyPathologyWake Forest School of MedicineFrankMariniFrank C. Marini PhD36.08943500000000-80.268632000000001107Marini, FrankProfessorEdwardLevineEdward A. Levine MD36.08959100000000-80.26859900000000273Levine, EdwardProfessorSamuelLentzSamuel S. Lentz MD36.08959100000000-80.26859900000000907Lentz, SamuelProfessorNeveenSaidNeveen Said MD, PhD36.09032400000000-80.266491000000001834Said, NeveenAssociate Professor31270077Tesfay L, Paul BT, Konstorum A, Deng Z, Cox AO, Lee J, Furdui CM, Hegde P, Torti FM, Torti SVCancer researchTesfay L, Paul BT, Konstorum A, Deng Z, Cox AO, Lee J, Furdui CM, Hegde P, Torti FM, Torti SV. Stearoyl-CoA Desaturase 1 Protects Ovarian Cancer Cells from Ferroptotic Cell Death. Cancer Res. 2019 10 15; 79(20):5355-5366.Cancer Res2019-07-03T00:00:002019Stearoyl-CoA Desaturase 1 Protects Ovarian Cancer Cells from Ferroptotic Cell Death.22Associate Professor32046380Teasley HE, Beesley A, Kim TH, Risinger J, Young SL, Jeong JW, Schammel DP, Lessey BA, Elder JW, Puls LReproductive sciences (Thousand Oaks, Calif.)Teasley HE, Beesley A, Kim TH, Risinger J, Young SL, Jeong JW, Schammel DP, Lessey BA, Elder JW, Puls L. Differential Expression of KRAS and SIRT1 in Ovarian Cancers with and Without Endometriosis. Reprod Sci. 2020 01; 27(1):145-151.Reprod Sci2020-01-01T00:00:002020Differential Expression of KRAS and SIRT1 in Ovarian Cancers with and Without Endometriosis.Obstetrics and Gynecology, GYN OncologySurgery, OncologyWake Forest Institute for Regenerative MedicineYanjunHouYanjun Hou3183Hou, YanjunAssistant Professor35552618Chae CS, Sandoval TA, Hwang SM, Park ES, Giovanelli P, Awasthi D, Salvagno C, Emmanuelli A, Tan C, Chaudhary V, Casado J, Kossenkov AV, Song M, Barrat FJ, Holcomb K, Romero-Sandoval EA, Zamarin D, Pépin D, D'Andrea AD, Färkkilä A, Cubillos-Ruiz JRCancer discoveryChae CS, Sandoval TA, Hwang SM, Park ES, Giovanelli P, Awasthi D, Salvagno C, Emmanuelli A, Tan C, Chaudhary V, Casado J, Kossenkov AV, Song M, Barrat FJ, Holcomb K, Romero-Sandoval EA, Zamarin D, Pépin D, D'Andrea AD, Färkkilä A, Cubillos-Ruiz JR. Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer. Cancer Discov. 2022 Aug 05; 12(8):1904-1921.Cancer Discov2022-08-05T00:00:002022Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer.37020040Jiang Y, Song L, Lin Y, Nowialis P, Gao Q, Li T, Li B, Mao X, Song Q, Xing C, Zheng G, Huang S, Jin LOncogeneJiang Y, Song L, Lin Y, Nowialis P, Gao Q, Li T, Li B, Mao X, Song Q, Xing C, Zheng G, Huang S, Jin L. ROS-mediated SRMS activation confers platinum resistance in ovarian cancer. Oncogene. 2023 May; 42(20):1672-1684.Oncogene2023-04-05T00:00:002023ROS-mediated SRMS activation confers platinum resistance in ovarian cancer.31734259Hou Y, Bruehl FK, McHugh KE, Reynolds JPJournal of the American Society of CytopathologyHou Y, Bruehl FK, McHugh KE, Reynolds JP. Primary tumor types and origins in positive abdominopelvic washing cytology, a single institution experience. J Am Soc Cytopathol. 2020; 9(2):89-94.J Am Soc Cytopathol2019-10-14T00:00:002019Primary tumor types and origins in positive abdominopelvic washing cytology, a single institution experience.true1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessor3.457930.032230343research area of0.9392950.0390303147subject area for